GRAIL
Highly Engaged Employees
Highly Engaged EmployeesHealthcare Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1525 O Brien Dr, Menlo Park, California,...Phone Number
(833) 694-2553Website
www.grail.comRevenue
$165.3 MillionStock Symbol
GRALIndustry
ZI Rank: 18
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
12
16
27
14
16
18
About GRAIL
GRAIL is a healthcare company dedicated to early cancer detection through innovative technologies, notably their Galleri test, which allows for multi-cancer early detection (MCED) by analyzing DNA in the bloodstream. The company aims to transform cancer screening and reduce mortality rates associated with cancer by utilizing advanced methylation analysis and machine-learning algorithms. Their intended clients include healthcare providers, oncologists, and individuals seeking proactive cancer screening solutions. GRAIL's mission focuses on changing the trajectory of cancer mortality by bringing together various stakeholders to adopt effective cancer detection technologies.Explore more
GRAIL Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GRAIL your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once GRAIL has new funding data
Earning: See what the market has to say on GRAIL recently announced quarterly report
Click to see if GRAIL had a recent Job posting/layoffs
Product Launch: Get notified when GRAIL launches new products
Website visits: Recent activity has been detected on your website
GRAIL, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GRAIL is spiking on competitors!
Check if GRAIL has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at GRAIL
Recommended Actions
Reach out to Masked Content who joined GRAIL as Masked Content
Find more new buyers
Compare Similar Companies to GRAIL
Compare insights from companies similar to GRAIL, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GRAIL is experiencing low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
GRAIL is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about GRAIL.
GRAIL financials insights
Gather financial insights about GRAIL, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$100M
2017
Series B
$900M
2018
Series C
$300M
2019
Unspecified
$125M
2020
Series D
$390M
2025
Stock/Share Issuance
$325M
2026
Stock/Share Issuance
$110M
GRAIL Tech Stack
A closer look at the technologies used by GRAIL
See more technologies
Most Recent Scoops
Person-Based
Partnership, Public Health
Person-Based
Artificial Intelligence
Person-Based
Healthcare Operations
Person-Based
Lawsuits, Legal Affairs
Person-Based
Lawsuits, Legal Affairs
GRAIL News & Media
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices. Speaking at the Canaccord Genuity Growth ConferenceGRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices...GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsJoshua Ofman - CEO & DirectorAaron Freidin - CFO & Head of...GRAIL Q2 Earnings Call Highlights
GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships. Revenue totaled $44.7 million in the second quarter, up 2
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GRAIL
Sign Up For FreeTo access detailed company insights
GRAIL is a healthcare company dedicated to early cancer detection through innovative technologies, notably their Galleri test, which allows for multi-cancer early detection (MCED) by analyzing DNA in the bloodstream. The company aims to transform cancer screening and reduce mortality rates associated with cancer by utilizing advanced methylation an... Read More
